Two non-profits sign a $36 million collaboration deal to develop drugs for the disease that claimed the life of the famed New York baseball player.
|
It’s pharmaceutical giant’s third drug development alliance in India in six months.
|
Concerns about cancer drugs overshadow successful drug launch, strong earnings, guidance.
|
Dealflow: Cellpoint Diagnostics gets $8.5M; Intent MediaWorks raises $1.2M.
|
The Microsoft co-founder’s financing built an atlas for one of the last medical frontiers, the brain.
|
A private equity firm sets out to beat cocaine with a vaccine. Tobacco comes next.
|
Meningitis program lowers costs, raises bar on collaboration.
|
Developer could be on to new class of drugs.
|
The battle builds over research data.
|
Red Herring magazine’s bioscience news briefs for the week of June 5, 2006.
|
Monthly anti-alcoholism injection gets approval in the U.S.
|
The technology is generating renewed interest in the VC and medical communities.
|
Dow-funded research suggests silicone implants don’t increase risk of breast cancer.
|
Growth is shifting, but the industry is none the poorer for that.
|
Bioscience news briefs for the week of April 10, 2006.
|
Rob Ashley is creating cancer drugs on a lean budget.
|
The U.S. Federal Trade Commission will investigate whether authorized generics flout competition laws.
|
Startup Nereus gets $18.3 million to look for new drugs in marine microbes.
|
Whether Wyeth’s bid to become more ‘biotech’ works or not, startups will benefit.
|
The country’s pharmaceutical firms grow up and out while multinationals move in, but the giants don’t always get what they want.
|
Page
1
of
3
|